Bruker Corporation Bruker Corporation

Bruker Corporation

BRKR

Rang in aandelen #2332
Bruker Corporation stands as a prominent global developer, manufacturer, and... Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Aandeelprijs
$55.23
Marktkapitalisatie
$8.42B
Verandering (1 dag)
-0.25%
Verandering (1 jaar)
44.93%
Land
US
Handel Bruker Corporation (BRKR)

Categorie

Healthcare
Aantal uitstaande aandelen voor Bruker Corporation (BRKR)
Aantal uitstaande aandelen per June 2026: 152.20M
Volgens de laatste financiële rapporten en de aandelenkoers van Bruker Corporation bedraagt het huidige aantal uitstaande aandelen 152.20M. Aan het einde van December 2024 had het bedrijf 149.00M uitstaande aandelen. Het aantal uitstaande aandelen wordt meestal beïnvloed door aandelensplitsingen en terugkoop van aandelen.
Geschiedenis van uitstaande aandelen van Bruker Corporation (BRKR) van 2000 tot 2026
Uitstaande aandelen aan het einde van elk jaar
Jaar Uitstaande aandelen Wijzigen
2026 (TTM) 152.20M 0.26%
2025 151.80M 1.88%
2024 149.00M 1.78%
2023 146.40M -1.48%
2022 148.60M -1.85%
2021 151.40M -1.30%
2020 153.40M -1.16%
2019 155.20M -0.64%
2018 156.20M -1.20%
2017 158.10M -2.04%
2016 161.40M -4.04%
2015 168.20M 0.24%
2014 167.80M 0.78%
2013 166.50M 0.30%
2012 166.00M 0.36%
2011 165.40M 0.61%
2010 164.40M 0.55%
2009 163.50M 0.49%
2008 162.70M 0.93%
2007 161.20M 58.80%
2006 101.51M 0.68%
2005 100.82M 4.62%
2004 96.38M -6.67%
2003 103.26M 96.31%
2002 52.60M -2.70%
2001 54.06M -3.89%
2000 56.25M 0.00%
Uitstaande aandelen van vergelijkbare bedrijven of concurrenten
Bedrijf Uitstaande aandelen Verschil Land
1.74B 1,045.24%
US
1.28B 742.38%
IE
383.50M 151.97%
US
1.48B 870.83%
US
- -
DE